NCT03020940

The Clinical Trial of Cefuroxime Axetil Dispersible Tablets

100000 Cases Real World Research of the Safety and Efficacy Revaluation of Cefuroxime Axetil Dispersible Tablets After Listing

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 100,000 (estimated)
• Sponsor: Jiangsu Famous Medical Technology Co., Ltd. · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

1. National, large-scale, standardized, standardized, real-world research; 2. Prospective, single - arm open, non - interventional, registration, multi - center clinical study; 3. in the use of cefuroxime axetil dispersible tablets in the hospital, according to the principle of voluntary selection of 200; 4. registration of the use of cefuroxime axetil dispersion tablets patients; 5. Target sample size of 100,000 cases; 6. Exemption from informed consent for ethical review applications; 7. Antibiotic drug safety re-evaluation of large data.

Detailed description

Research purposes 1. To evaluate the safety of cefuroxime axetil dispersible tablets in the real world of the widely used population, Rare or even very rare, new, unanticipated adverse reactions, while revealing adverse reactions Should be susceptible to risk factors and susceptible populations. 2. To evaluate the efficacy of cefuroxime axetil dispersible tablets in the treatment of the relevant site of infection, including Including empirical therapy and targeted therapy, to further evaluate the widespread use of cefuroxime dispersible tablets The validity of the crowd in the real world. 3. To investigate the clinical application of cefuroxime axetil dispersible tablets for the safety management of drug use. Clinical management should provide more clinical clues and basis. 4. For the relevant treatment areas of guidance and consensus revision, clinical pathway design provides a reference. 5. To further improve the safety of cefuroxime axetil dispersion tablets level, the basic medical security capabilities and Market vitality. Study end point 1. The main study endpoint: * Security; * Effectiveness. 2. Secondary study endpoint: * Extensive use of population characteristics; * Clinical drug characteristics; * Appropriate characteristics of the crowd; * Adverse reactions susceptible population characteristics.

Conditions

• Infectious Disease

Interventions

Type	Name	Description
DRUG	Cefuroxime Axetil Dispersible Tablets	Oral. This product can be taken orally, can also be added to the amount of warm water after mixing evenly. Adult general 0.25g (one time), 2 times a day, the general course of treatment for 5 to 10 days. Severe Infection or suspected pneumonia, a 0.5g (once 2), 2 times a day; general urinary tract infection, a Times a 0.125g (one and a half tablets), 2 times a day; for patients with no complications of gonorrhea recommended dose of 1g (4 Tablets), a single taking. Children generally a dose of 0.125g (one-half tablets), 2 times a day; for less than two years of age in the middle ear Inflammatory patients, a 0.125g (one half tablets), 2 times a day; for greater than two years of otitis media patients, one Times a 0.25g (one time), 2 times a day; more than 12 years of age in children, the same dose for adults

Timeline

• Start date: 2017-01-01
• Primary completion: 2019-11-01
• Completion: 2019-11-01
• First posted: 2017-01-13
• Last updated: 2017-01-13